Aristea Therapeutics

Recent Finacing

Series B

Recent Raise

$63M

Aristea Therapeutics is a clinical-stage immunology drug developer creating therapies for inflammatory and orphan diseases, advancing lead program RIST4721 in Phase 2 clinical trials with industry collaborations.

Founded 2018

California, United States

1-10

Private

aristeatx.com

Highlights

Focus Areas

Biotechnology

Medical

Pharmaceutical

Recent Investors

Financials

$78M

Total Raised

2

Funding rounds

4

Investors

Team

Upgrade to view the team

See the team members at Aristea Therapeutics.